From Suppressing Symptoms to Restoring Wakefulness Signaling: FDA Approves First Orexin Receptor Agonist

Treatment for narcolepsy type 1 has long resembled fighting separate fires: different drugs are used to alleviate excessive daytime sleepiness, cataplexy, or disrupted nighttime sleep, without directly addressing the biological deficit that destabilizes the boundary between sleep and wakefulness. The U.S. Food and Drug Administration (FDA) has now approved Takeda Pharmaceutical’s Orzeyful (oveporexton), the first treatment in the United States to directly restore orexin signaling and address the major symptoms of this disease.

Patients with narcolepsy type 1 experience extensive loss of neurons that produce orexin, also known as hypocretin. As a result, they have difficulty maintaining wakefulness and are prone to suddenly experiencing rapid eye movement sleep-like phenomena while awake, including cataplexy, a sudden loss of muscle tone. Oveporexton is an oral, selective orexin receptor 2 agonist that strengthens signaling by stimulating the receptors that remain. It does not regenerate the lost neurons and therefore does not constitute a cure for the disease.

The approval was based primarily on FirstLight and RadiantLight, two 12-week, multicenter, placebo-controlled Phase 3 trials. FirstLight enrolled 168 adults divided into three groups, while RadiantLight enrolled 105 adults divided into two groups, for a combined total of 273 participants. The FDA said the treatment groups outperformed placebo on measures including objective wakefulness, weekly cataplexy frequency, and patient-reported symptoms, allowing a single drug to address symptom domains that previously often required separate treatment.

Takeda also reported that treated participants improved across all six domains of daily functioning at Week 12. About 70% of participants reported no longer having meaningful cognitive difficulties, compared with approximately 15% in the placebo group. These functional and cognitive data offer indications of everyday-life effects beyond rating scales, but the figures come from the company’s analysis of secondary trial outcomes and should still be interpreted alongside the full study reports and future real-world data.

The more common adverse events in the short-term trials included insomnia, urinary urgency, and frequent urination. More than 95% of participants who completed the pivotal trials entered a long-term extension study, which will support further follow-up. However, the placebo-controlled period currently supporting the approval lasted only 12 weeks. For a drug that may be used for life, whether its efficacy is sustained, its rare side effects, and the effects of discontinuation have not yet been fully clarified.

The independent Institute for Clinical and Economic Review concluded that oveporexton is likely to provide a substantial net health benefit compared with no pharmacologic treatment, assigning it a B+ evidence rating. However, the pivotal trials did not directly compare it with existing therapies such as modafinil-class drugs, sodium oxybate, or pitolisant, so it is not yet possible to determine whether it is comprehensively superior in efficacy, safety, or treatment burden.

The significance of this approval lies not merely in adding another wake-promoting drug, but in demonstrating that a mechanism targeting orexin deficiency can address multiple symptom domains and reach clinical use. Long-term extension studies, postmarketing surveillance, and real-world comparisons with existing treatments will determine whether this biological breakthrough can truly reshape the daily care of narcolepsy type 1.